Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Joss, N.
Right arrow Articles by Boulton-Jones, J.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Joss, N.
Right arrow Articles by Boulton-Jones, J.M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 2002; 95: 41-49
© 2002 Association of Physicians

Diabetic nephropathy: how effective is treatment in clinical practice?

N. Joss, K.R. Paterson1, C.J. Deighan, K. Simpson and J.M. Boulton-Jones

From the Renal Unit and 1 Diabetic Unit, Glasgow Royal Infirmary, Glasgow, UK

Received 7 August 2001 and in revised form 26 October 2001

Background: Diabetic nephropathy is the most common cause of end-stage renal failure in patients starting dialysis in the developed world. In clinical trials, interventions, particularly blood pressure control, have achieved major reductions in the rate of decline in renal function.

Aim: To investigate whether results from clinical trials can be achieved in routine clinical practice.

Design: Observational study of 170 consecutive patients referred to a combined diabetic-renal clinic over a 10 year period.

Methods: We collected demographic and laboratory data from the electronic patient record.

Results: Median serum creatinine at referral was 170 µmol/l and was >350 µmol/l in 26% of patients. Mean blood pressure (BP) was 159/85. The publication of guidelines by the Scottish Intercollegiate Guidelines Network in 1997, recommending more active intervention and earlier referral, had no impact on referral BP and creatinine. In the 125 patients with at least 1 year follow-up, significant improvements in BP, albuminuria, HbA1c and serum cholesterol were seen. In the 63 patients followed up for 3 years (median creatinine 120 µmol/l), the median rate of decline in renal function slowed from 0.52 ml/min/month (first year) to 0.27 ml/min/month (third year) (p=0.003), nearly doubling the time to end-stage renal failure.

Discussion: Patients referred early to a combined diabetic-renal clinic benefited by slowing in the rate of decline of renal function. A challenging but achievable standard for audit would be to reduce the rate of progression to <0.25 ml/min/month in 70% of patients with diabetic nephropathy presenting with a serum creatinine <150 µmol/l.

Address correspondence to Dr N. Joss, Renal Unit, Glasgow Royal Infirmary, 84 Castle Street, Glasgow G4 0SF. e-mail: njoss{at}compuserve.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
British Journal of Diabetes & Vascular DiseaseHome page
C. J. Kelly and G. Booth
Pharmacist-led structured care for patients with diabetic nephropathy
The British Journal of Diabetes & Vascular Disease, March 1, 2008; 8(2): 86 - 88.
[Abstract] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.